Myeloid-derived suppressor cells--their role in haemato-oncological malignancies and other cancers and possible implications for therapy.
about
Myeloid-derived suppressor cells as therapeutic target in hematological malignanciesClinical Impact of the Immunome in Lymphoid Malignancies: The Role of Myeloid-Derived Suppressor CellsTumor-derived G-CSF facilitates neoplastic growth through a granulocytic myeloid-derived suppressor cell-dependent mechanism.CXCL17 expression by tumor cells recruits CD11b+Gr1 high F4/80- cells and promotes tumor progression.Addition of granulocyte macrophage colony stimulating factor does not improve response to early treatment of high-risk chronic lymphocytic leukemia with alemtuzumab and rituximab.Myeloid derived suppressor cells in chronic myeloid leukemia.Murine gammaherpesvirus-68 expands, but does not activate, CD11b+ gr-1+ splenocytes in vivoAn expanded myeloid derived suppressor cell population does not play a role in gammaherpesvirus-exacerbated breast cancer metastases.Myeloid-derived suppressor cells function as novel osteoclast progenitors enhancing bone loss in breast cancer.Cryo-thermal therapy elicits potent anti-tumor immunity by inducing extracellular Hsp70-dependent MDSC differentiation.Tumor microenvironment: a main actor in the metastasis process.Myeloid-derived suppressor cells (MDSCs) in gliomas and glioma-development.Mechanisms of action of tasquinimod on the tumour microenvironment.Myeloid-derived suppressor cells: their role in the pathophysiology of hematologic malignancies and potential as therapeutic targets.Myeloid-derived suppressor cells in B cell malignancies.Challenges in vaccine therapy in hematological malignancies and strategies to overcome them.Progress and opportunities for immune therapeutics in osteosarcoma.Cytotoxicity of tumor antigen specific human T cells is unimpaired by arginine depletion.Targeting immune suppression with PDE5 inhibition in end-stage multiple myeloma.Myeloid-derived suppressor cell measurements in fresh and cryopreserved blood samples.Peripheral blood absolute lymphocyte/monocyte ratio as a useful prognostic factor in diffuse large B-cell lymphoma in the rituximab era.Therapeutic reduction of cell-mediated immunosuppression in mycosis fungoides and Sézary syndrome.Absolute monocytosis at diagnosis correlates with survival in diffuse large B-cell lymphoma-possible link with monocytic myeloid-derived suppressor cells.Treatment with lenalidomide induces immunoactivating and counter-regulatory immunosuppressive changes in myeloma patients.Hierarchical Involvement of Myeloid-Derived Suppressor Cells and Monocytes Expressing Latency-Associated Peptide in Plasma Cell Dyscrasias.Granulocytic myeloid-derived suppressor cells inversely correlate with plasma arginine and overall survival in critically ill patients.
P2860
Q27010234-AE71CB46-58FD-4683-AA1A-443FFDD33720Q28083973-E7AB3A73-D66A-45D1-A2F1-B4E7F2AE5DA7Q34081723-5340E672-4E59-4B70-9D2F-579480C75A71Q34406206-D18CCA57-DA7D-4E73-8B1F-E58D7A305C2EQ35569491-DEF9D140-0B49-4B1B-8961-1AFFDD9E2A32Q35609094-DE8D2CDF-3B9C-446F-9A92-3344B905EB7EQ36202912-A1F11FFC-12F8-4E4E-9BC6-DF2B2D9D6017Q36299452-9FA4FCBB-1933-47A0-BB09-F6DC68BA7536Q36544980-6E28F4B3-0E5A-40AA-B68F-5A2288C0B613Q36964967-47CFA9DD-ECA1-4A46-A695-1C71A8119352Q37982937-147F7A9B-FFE4-49AF-99A6-25BEF45CFE1BQ38047053-D05F3A44-F48F-4479-A0A0-376EAE0CC7C5Q38155757-30C62ECC-0D39-4730-BCC4-90371EACE341Q38269370-067578BD-2A13-4146-82BC-E7E5398B8569Q38578686-7769A061-A6D1-4EB2-A0E6-135E288E313EQ38843235-5AC64557-453F-4BF9-A7B7-F6F3BCA460F2Q38948905-36AD8305-7303-4CE2-8C3F-491D1003D2E4Q40983895-D2E5DE08-69F4-4D16-ABED-BF1373E294F8Q42014659-7D38CA80-B627-4DD2-8FB0-AA2E8BBC6536Q42219156-A1F09599-A2B3-4681-B3A9-A1D79B6C55BAQ44404015-3EF4EB12-14FF-4B2D-9B9E-A20C9F622A66Q46248185-0B78A650-CEF0-4058-BB6C-9B135FBD8416Q47600079-891AC4C6-2AE1-448F-A266-8FE60770E37BQ50853922-45298AE2-07BC-4885-B48A-E8309DD197CEQ52723606-90C94A8D-F550-4A05-841D-0671BE965179Q53160619-04A67D74-C20C-4232-906C-3C0833ED2A05
P2860
Myeloid-derived suppressor cells--their role in haemato-oncological malignancies and other cancers and possible implications for therapy.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 08 April 2011
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Myeloid-derived suppressor cel ...... ible implications for therapy.
@en
Myeloid-derived suppressor cel ...... ible implications for therapy.
@nl
type
label
Myeloid-derived suppressor cel ...... ible implications for therapy.
@en
Myeloid-derived suppressor cel ...... ible implications for therapy.
@nl
prefLabel
Myeloid-derived suppressor cel ...... ible implications for therapy.
@en
Myeloid-derived suppressor cel ...... ible implications for therapy.
@nl
P2093
P2860
P1476
Myeloid-derived suppressor cel ...... ible implications for therapy.
@en
P2093
Aaron Polliack
Dina Attias
Tamar Tadmor
P2860
P304
P356
10.1111/J.1365-2141.2011.08678.X
P407
P577
2011-04-08T00:00:00Z